Patents by Inventor Christiane Neumann
Christiane Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043535Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: December 16, 2022Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
-
Publication number: 20240018240Abstract: The present invention generally relates to antibodies that bind to CD3 and PLAP, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 8, 2022Publication date: January 18, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Ali Bransi, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Kerstin Hofer, Thomas Hofer, Tommy Kuehnl, Ekkehard Moessner, Christiane Neumann
-
Publication number: 20230340160Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: April 17, 2023Publication date: October 26, 2023Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Publication number: 20230287118Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: October 13, 2022Publication date: September 14, 2023Inventors: Oliver AST, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20230287145Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: ApplicationFiled: December 15, 2022Publication date: September 14, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Peter BRUENKER, Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN
-
Publication number: 20230159642Abstract: The present invention relates to antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations, and methods of using the same.Type: ApplicationFiled: October 18, 2022Publication date: May 25, 2023Inventors: Alexander BUJOTZEK, Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Carina HAGE, Thomas HOFER, Silke KIRCHNER, Meher MAJETY, Ekkehard MOESSNER, Christiane NEUMANN, Christian SPICK, Georg TIEFENTHALER, Thomas WEINDL
-
Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
Patent number: 11639397Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: May 5, 2014Date of Patent: May 2, 2023Assignee: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umana -
Publication number: 20230076791Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 25, 2022Publication date: March 9, 2023Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20220403027Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: April 1, 2022Publication date: December 22, 2022Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Patent number: 11459404Abstract: The present invention generally relates to bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: July 20, 2017Date of Patent: October 4, 2022Assignee: Roche Glycart AGInventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Publication number: 20220213199Abstract: The present invention relates antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations and methods of using the same.Type: ApplicationFiled: December 15, 2021Publication date: July 7, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Carina Hage, Thomas Hofer, Silke Kirchner, Meher Majety, Ekkehard Moessner, Christiane Neumann, Christian Spick, Georg Tiefenthaler, Thomas Weindl
-
Publication number: 20220213224Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 9, 2021Publication date: July 7, 2022Inventors: Christian KLEIN, Ekkehard MOESSNER, Ralf HOSSE, Peter BRUENKER, Pablo UMANA, Christiane NEUMANN
-
Publication number: 20220064296Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: November 12, 2021Publication date: March 3, 2022Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20220010015Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: June 17, 2021Publication date: January 13, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN, Pablo Umaña
-
Patent number: 11117965Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: February 24, 2020Date of Patent: September 14, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20210253703Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 3, 2021Publication date: August 19, 2021Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20210101979Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: December 18, 2020Publication date: April 8, 2021Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20210070882Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 18, 2020Publication date: March 11, 2021Inventors: Marina BACAC, Christian KLEIN, Wolfgang SCHAEFER, Stefan KLOSTERMANN, Sabine IMHOF-JUNG, Michael MOLHOJ, Joerg Thomas REGULA, Pablo UMANA, Sylvia HERTER, Christiane NEUMANN
-
Publication number: 20200347147Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 23, 2020Publication date: November 5, 2020Inventors: Marina BACAC, Tanja FAUTI, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Ekkehard MOESSNER, Michael MOLHOJ, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20200325224Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: January 23, 2020Publication date: October 15, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter